Negative-Beta Stocks: Worth Buying?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Investors always want great returns with minimal risk. One way that stock analysts measure risk is by looking at what's known as beta values, with higher betas representing more volatile stocks. But if high-beta stocks are risky and low-beta stocks are safer, could negative-beta stocks be the best deal of all?

A brief look at beta
Understanding beta involves breaking down the component parts of a stock's return. One part, called alpha, represents the return that's completely independent of the stock market. The other, beta, shows the extent to which the stock's return is correlated to the stock market's overall return. As a result, high-beta stocks tend to produce bigger gains when stocks rise -- and bigger losses when they fall -- than their low-beta counterparts.

Negative-beta stocks, however, have odd behavior because they tend to move in the direction opposite the market's movement. Most frequently, discussions of negative beta will center around bonds, because bond investments tend to rise when stocks fall and vice versa. For individual stocks, though, negative betas are fairly rare.

But out of curiosity, I turned up some of the few negative-beta stocks out there. Here's a quick look.

Arena Pharmaceuticals (NASDAQ: ARNA  ) , beta = -0.32
Arena is a small drugmaker with a blockbuster new product: anti-obesity drug Belviq. After long waits to get FDA approval, Arena and competitor VIVUS (NASDAQ: VVUS  ) both successfully got drugs on the market, the first to fight obesity in years.

Here, the negative beta doesn't represent any sort of anti-market sentiment. Rather, it simply reflects the fact that Arena's movements are determined much more by company-specific news like Belviq's sales than by overall market action. Investors shouldn't look at Arena as being low-risk just because of its negative beta.

Ferrellgas Partners (NYSE: FGP  ) , beta = -0.01
Ferrellgas is a propane supplier that's best known for its Blue Rhino refillable gas tanks for grills and other household uses. Given the fairly constant need for its products, Ferrellgas has seen solid demand, and as a master limited partnership, it pays a healthy dividend yield to investors.

Recession-resistant businesses like Ferrellgas often have little or no correlation to the market. In this case, a negative beta just a hair under 0 doesn't have any more significance than a positive 0.01 beta would. Ferrellgas will move with gas prices more than with the broad market.

Agnico-Eagle Mines (NYSE: AEM  ) , beta = -0.33
As a mining company, Agnico-Eagle produces gold, and lately, it has had some big success. The company has had to boost its production estimates for the full 2012 year twice, with its latest guidance pointing to more than 1 million ounces of gold production. With cash costs on the decline, Agnico-Eagle has posted a strong advance recently.

Gold and other precious-metals producers often move against the market, because gold often attracts safe-haven money when stocks start to decline. That relationship has fallen lately, which explains why the negative beta is relatively low, but many investors use gold miners like Agnico-Eagle as hedges to diversify their portfolio exposure.

Dr Pepper Snapple (NYSE: DPS  ) , beta = -0.11
As a distant third in the soft-drink wars, Dr Pepper is understandably insulated from the moves of the overall market. With its own niche from its unique namesake beverage, Dr Pepper has found ways to sustain its business regardless of the strategies of its larger competitors.

Big stocks tend to be included in index funds that increase correlation, but smaller companies like Dr Pepper often avoid that effect. Dr Pepper is a relatively safe stock with a devoted customer base that sees the product as a necessity, and that should support demand going forward.

The right way to invest in negative-beta stocks
The key to investing in these unusual stocks is not to draw generalizations based on beta. Instead, you have to look at each stock to determine why the beta is negative, and then decide if it's a good fit for your portfolio.

Among these negative-beta stocks, Arena arguably has the most potential, as the potential market for obesity drugs is massive. To learn more about Arena and its chief competitor, grab your copies of our premium research reports on Arena Pharmaceuticals and VIVUS today. In the reports, our senior biotech analyst, Brian Orelli, Ph.D., breaks down each company's strengths and weaknesses, and explains the critical issues you need to know about. News in this space moves fast, so both reports come with a full year of updates. Click now for exclusive information on Arena and VIVUS.

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 13, 2012, at 10:51 PM, stockman1948 wrote:

    latest update on Arena Pharmaceuticals

    ********ATTENTION ARNA INVESTORS*********

    What you are seeing below is taken direct from the most recent conference held by ARNA at NYC. This is an actual account of $$$ received and what is expected on announcement of the DEA scheduling. I suggest that you open and view what was said by ARNA executives and read the facts for yourself.

    • $55M in upfront payments received

    • $20M milestone payment received – FDA-approved prescribing information includes efficacy & safety data from BLOOM-DM

    • $65M following DEA scheduling

    • Eligible to receive up to an additional $54.5M in regulatory & development milestone payments


    This is an incredible amount of dollars that ARNA has earned and is projected to receive on the DEA scheduling and this is why many investors are confident that ARNA stock will skyrocket.

    STOKMAN 1948

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2150677, ~/Articles/ArticleHandler.aspx, 10/24/2016 8:16:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,223.03 77.32 0.43%
S&P 500 2,151.33 10.17 0.47%
NASD 5,309.83 52.43 1.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2016 4:02 PM
AEM $48.29 Down -0.76 -1.55%
Agnico-Eagle Mines CAPS Rating: **
ARNA $1.59 Up +0.02 +1.27%
Arena Pharmaceutic… CAPS Rating: **
DPS $88.32 Up +0.46 +0.52%
Dr. Pepper Snapple… CAPS Rating: ***
FGP $10.50 Down -0.03 -0.28%
Ferrellgas Partner… CAPS Rating: *
VVUS $1.12 Up +0.02 +1.82%
VIVUS CAPS Rating: **